The Manufacturers Life Insurance Company increased its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 154.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 65,238 shares of the company's stock after purchasing an additional 39,640 shares during the period. The Manufacturers Life Insurance Company owned 0.12% of Dianthus Therapeutics worth $5,475,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. SummitTX Capital L.P. raised its holdings in shares of Dianthus Therapeutics by 13.8% in the first quarter. SummitTX Capital L.P. now owns 100,044 shares of the company's stock valued at $8,396,000 after buying an additional 12,118 shares during the last quarter. ABS Direct Equity Fund LLC purchased a new position in shares of Dianthus Therapeutics during the first quarter worth about $179,000. Spruce Street Capital LP grew its holdings in shares of Dianthus Therapeutics by 25.5% during the first quarter. Spruce Street Capital LP now owns 373,274 shares of the company's stock worth $31,325,000 after buying an additional 75,837 shares during the last quarter. Sei Investments Co. grew its holdings in shares of Dianthus Therapeutics by 566.3% during the first quarter. Sei Investments Co. now owns 92,229 shares of the company's stock worth $7,741,000 after buying an additional 78,388 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in Dianthus Therapeutics by 0.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company's stock valued at $3,135,000 after acquiring an additional 139 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the company. Wall Street Zen raised Dianthus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, May 9th. Wolfe Research reissued an "outperform" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Weiss Ratings restated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Raymond James Financial reaffirmed a "strong-buy" rating and set a $131.00 price target on shares of Dianthus Therapeutics in a report on Wednesday. Finally, Wedbush lifted their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an "outperform" rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $124.27.
View Our Latest Stock Analysis on Dianthus Therapeutics
Dianthus Therapeutics Stock Down 2.3%
Shares of NASDAQ:DNTH opened at $109.92 on Friday. Dianthus Therapeutics, Inc. has a 52 week low of $18.08 and a 52 week high of $114.55. The company has a 50-day moving average price of $94.40 and a 200 day moving average price of $80.45. The company has a market cap of $6.01 billion, a P/E ratio of -26.49 and a beta of 1.22.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. Analysts expect that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.
Insider Activity at Dianthus Therapeutics
In related news, SVP Adam M. Veness sold 30,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total value of $2,424,000.00. Following the sale, the senior vice president directly owned 30,000 shares in the company, valued at $2,424,000. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president owned 31,249 shares of the company's stock, valued at $3,157,086.47. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 87,779 shares of company stock worth $7,985,235 over the last three months. 3.02% of the stock is currently owned by corporate insiders.
Dianthus Therapeutics Company Profile
(
Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
See Also
Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
